Exploring metabolic subtypes of non-alcoholic fatty liver disease using machine learning
Machine Learning to Identify Metabolic Subtypes of Non-Alcoholic Fatty Liver Disease
This study is trying to use advanced computer techniques to better understand different types of non-alcoholic fatty liver disease in patients, so doctors can predict risks and tailor treatments more effectively.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT05560997 on ClinicalTrials.gov |
What this trial studies
This study aims to refine the classification of non-alcoholic fatty liver disease (NAFLD) subgroups through machine learning techniques. By analyzing clinical characteristics of patients with biopsy-proven NAFLD, the study seeks to develop a more precise metabolic classification that can better predict prognosis and inform individualized therapy. The research involves clustering patients based on clinical variables and verifying these clusters in a longitudinal cohort, ultimately aiming to identify those at higher risk for cardiovascular disease or cirrhosis.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 75 years with biopsy-proven NAFLD who have complete clinical information.
Not a fit: Patients with excessive alcohol consumption or other liver diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for patients with NAFLD, improving their health outcomes.
How similar studies have performed: While the approach of using machine learning for classification in NAFLD is innovative, similar studies have shown promise in refining disease classifications in other conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * biopsy-proved NALD cohort: 1. age 18 to 75 years 2. receiving liver biopsy at the time of metabolic surgery 3. relatively complete clinical information, including physical examination, biochemical and haematological assessments * longitudinal cohort 1. age 18 to 75 years 2. receiving abdominal imaging examinations, 3. relatively complete clinical information, including physical examination, biochemical and haematological assessments (4）follow-up time at least more than 12 months Exclusion Criteria: * (1)consumed excessive alcohol (≥140 g/week for males or ≥ 70 g/week for females) • * (2) with history of other liver diseases including chronic hepatitis, biliary obstructive diseases or autoimmune hepatitis
Where this trial is running
Nanjing, Jiangsu
- Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University — Nanjing, Jiangsu, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.